SYRE

Spyre Therapeutics, Inc.$81.33+0.56 (+0.69%)

Prev Close$80.77·MCap$4.88B·P/E—·Vol444.9K·Yield—

▲

Buys (12M)

$0.00

▼

Sells (12M)

$19.97M

◆

Net Activity

Net Seller

$19.97M

●

Active Insiders

last 12 mo

Over the past 12 months, insider activity at Spyre Therapeutics, Inc. (SYRE) has been exclusively selling, with 0 insider purchases totaling $0.00 and 15 insider sales totaling $19.97M. The most recent insider transaction was by Turtle Cameron (director, officer: Chief Executive Officer), who sold $1.06M worth of shares on Jun 3, 2026. Spyre Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $4.88B.

SYRE Insider Trading Activity

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Jun 3, 2026	Turtle Cameron	director, officer: Chief Executive Officer	Sell	15,000	$70.43	$1.06M	608,983
Jun 3, 2026	Burrows Scott L	officer: Chief Financial Officer	Sell	7,500	$71.06	$532.9K	103,693
Jun 3, 2026	Sloan Sheldon	officer: Chief Medical Officer	Sell	8,333	$75.00	$625.0K	0Exit
May 8, 2026	HENDERSON MICHAEL THOMAS	director	Sell	80,000	$74.40	$5.95M	166,202-32%
May 1, 2026	Burrows Scott L	officer: Chief Financial Officer	Sell	12,500	$71.37	$892.1K	97,994
May 1, 2026	Sloan Sheldon	officer: Chief Medical Officer	Sell	78,333	$71.50	$5.60M	57,027-58%
May 1, 2026	Turtle Cameron	director, officer: Chief Executive Officer	Sell	15,000	$71.37	$1.07M	622,240
Apr 3, 2026	Burrows Scott L	officer: Chief Financial Officer	Sell	7,500	$49.34	$370.1K	99,294
Apr 3, 2026	Sloan Sheldon	officer: Chief Medical Officer	Sell	7,958	$50.00	$397.9K	0Exit
Apr 3, 2026	Turtle Cameron	director, officer: Chief Executive Officer	Sell	15,000	$49.33	$739.9K	630,196
Feb 2, 2026	Turtle Cameron	Chief Executive Officer	Sell	15,000	$32.80	$492.0K	0
Jan 2, 2026	Turtle Cameron	Chief Executive Officer	Sell	15,000	$30.68	$460.1K	0
Dec 1, 2025	Turtle Cameron	Chief Executive Officer	Sell	15,000	$29.02	$435.4K	0
Nov 3, 2025	Turtle Cameron	Chief Executive Officer	Sell	45,000	$23.33	$1.05M	0
Sep 2, 2025	Burrows Scott L	Chief Financial Officer	Sell	18,428	$16.26	$299.6K	0
Nov 8, 2024	Albers Jeffrey W.	Director	Sell	6,700	$36.76	$246.3K	27,360
Oct 28, 2024	Albers Jeffrey W.	Director	Sell	300	$36.43	$10.9K	34,060
Sep 5, 2024	Burrows Scott L	Chief Financial Officer	Sell	18,531	$28.17	$522.1K	116,422
Aug 25, 2022	Souza Marcio	Director	Buy	90,000	$0.56	$50.5K	90,000
Jun 10, 2022	Hanley Jr. Michael Conick	Chief Commercial Officer	Buy	28,200	$0.71	$20.0K	36,200+353%
Mar 18, 2022	Quinn Anthony G.	President & CEO	Buy	80,079	$2.34	$187.7K	550,540
Mar 15, 2022	Alspaugh Jonathan	Chief Financial Officer	Buy	75,000	$2.08	$156.0K	165,372+83%
Mar 15, 2022	Quinn Anthony G.	President & CEO	Buy	144,666	$1.94	$280.9K	473,461+44%
Dec 13, 2021	Alspaugh Jonathan	Chief Financial Officer	Buy	50,000	$3.72	$186.0K	90,372+124%
Dec 13, 2021	Quinn Anthony G.	President & CEO	Buy	53,634	$3.71	$199.0K	328,795
Dec 13, 2021	Shanafelt Armen	Director	Buy	150,000	$3.66	$549.7K	150,000
Aug 18, 2021	Alspaugh Jonathan	Chief Financial Officer	Buy	40,372	$6.51	$262.7K	40,372

SYRE Insider Buying Activity

The following table shows recent insider purchases of Spyre Therapeutics, Inc. (SYRE) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Aug 25, 2022	Souza Marcio	Director	Buy	90,000	$0.56	$50.5K	90,000
Jun 10, 2022	Hanley Jr. Michael Conick	Chief Commercial Officer	Buy	28,200	$0.71	$20.0K	36,200+353%
Mar 18, 2022	Quinn Anthony G.	President & CEO	Buy	80,079	$2.34	$187.7K	550,540
Mar 15, 2022	Alspaugh Jonathan	Chief Financial Officer	Buy	75,000	$2.08	$156.0K	165,372+83%
Mar 15, 2022	Quinn Anthony G.	President & CEO	Buy	144,666	$1.94	$280.9K	473,461+44%
Dec 13, 2021	Alspaugh Jonathan	Chief Financial Officer	Buy	50,000	$3.72	$186.0K	90,372+124%
Dec 13, 2021	Quinn Anthony G.	President & CEO	Buy	53,634	$3.71	$199.0K	328,795
Dec 13, 2021	Shanafelt Armen	Director	Buy	150,000	$3.66	$549.7K	150,000
Aug 18, 2021	Alspaugh Jonathan	Chief Financial Officer	Buy	40,372	$6.51	$262.7K	40,372

SYRE Insider Selling Activity

The following table shows recent insider sales of Spyre Therapeutics, Inc. (SYRE) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Jun 3, 2026	Turtle Cameron	director, officer: Chief Executive Officer	Sell	15,000	$70.43	$1.06M	608,983
Jun 3, 2026	Burrows Scott L	officer: Chief Financial Officer	Sell	7,500	$71.06	$532.9K	103,693
Jun 3, 2026	Sloan Sheldon	officer: Chief Medical Officer	Sell	8,333	$75.00	$625.0K	0Exit
May 8, 2026	HENDERSON MICHAEL THOMAS	director	Sell	80,000	$74.40	$5.95M	166,202-32%
May 1, 2026	Burrows Scott L	officer: Chief Financial Officer	Sell	12,500	$71.37	$892.1K	97,994
May 1, 2026	Sloan Sheldon	officer: Chief Medical Officer	Sell	78,333	$71.50	$5.60M	57,027-58%
May 1, 2026	Turtle Cameron	director, officer: Chief Executive Officer	Sell	15,000	$71.37	$1.07M	622,240
Apr 3, 2026	Burrows Scott L	officer: Chief Financial Officer	Sell	7,500	$49.34	$370.1K	99,294
Apr 3, 2026	Sloan Sheldon	officer: Chief Medical Officer	Sell	7,958	$50.00	$397.9K	0Exit
Apr 3, 2026	Turtle Cameron	director, officer: Chief Executive Officer	Sell	15,000	$49.33	$739.9K	630,196
Feb 2, 2026	Turtle Cameron	Chief Executive Officer	Sell	15,000	$32.80	$492.0K	0
Jan 2, 2026	Turtle Cameron	Chief Executive Officer	Sell	15,000	$30.68	$460.1K	0
Dec 1, 2025	Turtle Cameron	Chief Executive Officer	Sell	15,000	$29.02	$435.4K	0
Nov 3, 2025	Turtle Cameron	Chief Executive Officer	Sell	45,000	$23.33	$1.05M	0
Sep 2, 2025	Burrows Scott L	Chief Financial Officer	Sell	18,428	$16.26	$299.6K	0
Nov 8, 2024	Albers Jeffrey W.	Director	Sell	6,700	$36.76	$246.3K	27,360
Oct 28, 2024	Albers Jeffrey W.	Director	Sell	300	$36.43	$10.9K	34,060
Sep 5, 2024	Burrows Scott L	Chief Financial Officer	Sell	18,531	$28.17	$522.1K	116,422